Total-body PET for personalised radioligand dosing
Ultra-sensitive whole-body scanners can measure exactly where a radioactive drug goes at tiny tracer doses, allowing each patient's therapeutic dose to be tailored.
Radioligand therapy is given at fixed activity despite 10-fold variation in tumour and kidney dose. Total-body PET with 44Sc- or 89Zr-labelled analogues can quantify pharmacokinetics before treatment.
Pages like this
not linked directly; found by shared links- TechnologyNuclear medicine and total-body PET hardware
Shares United Imaging, Siemens Healthineers, SPECT & bone scan, PET/CT.
- TechnologyTotal-body PET for screening and ultra-low-dose imaging
Shares United Imaging, Siemens Healthineers, Dosimetry, PET/CT.
- PairingPSMA PET → PSMA radioligand therapy
Shares Qualify PSMA PET tumour volume as a validated imaging biomarker, Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters), Prostate cancer.
- IdeaAlpha-emitting PSMA therapy at first metastatic diagnosis
Shares Dosimetry, Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters), Prostate cancer.
- IdeaDosimetry-personalised PRRT instead of four fixed cycles
Shares SPECT & bone scan, Dosimetry, Wrong doses.
- InstitutionSociety of Nuclear Medicine and Molecular Imaging
Shares SPECT & bone scan, Dosimetry, Lutetium-177 vipivotide tetraxetan, PET/CT.
- InstitutionChulabhorn Hospital / Chulabhorn Royal Academy
Shares Lutetium-177 vipivotide tetraxetan, PET/CT, Radioligand therapy (beta emitters), Prostate cancer.
- TrialPSMAddition
Shares Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters), Prostate cancer.